Circulating annexin A5 predicts mortality in patients with heart failure

L. J. Schurgers, M. Burgmaier, T. Ueland, K. Schutters, S. Aakhus, L. Hofstra, L. Gullestad, P. Aukrust, M. Hellmich, J. Narula, C. P. Reutelingsperger*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background Natriuretic peptides are currently used to predict mortality in patients with heart failure (HF). However, novel independent biomarkers are needed to improve risk stratification in these patients. We hypothesized that annexin A5 (anxA5) would be highly expressed by organs which are generally affected by HF and that circulating anxA5 levels would predict mortality in HF patients. MethodsWe prospectively determined the diagnostic value of anxA5, N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and estimated glomerular filtration rate (eGFR) to predict mortality in 180 HF patients during a median follow-up of 3.6years. Studies were conducted with anxA5(-/-) mice to investigate the underlying mechanisms. ResultsAnxA5 levels were significantly elevated in HF patients compared to healthy control subjects. Cox regression analysis demonstrated that anxA5, NT-proBNP and eGFR all predict mortality independently. AnxA5 significantly improved the diagnostic efficiency of NT-proBNP alone (improvement of c-statistic from 0.662 to 0.705, P
Original languageEnglish
Pages (from-to)89-97
JournalJournal of Internal Medicine
Issue number1
Publication statusPublished - Jan 2016


  • annexin A5
  • apoptosis
  • biomarkers
  • heart
  • heart failure

Cite this